BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CSPC ZhongQi Pharmaceutical Technology Co.\, Ltd. readouts · 
 AssetMemo
X-WR-CALDESC:Upcoming readouts of studies CSPC ZhongQi Pharmaceutical Techn
 ology Co.\, Ltd.'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06525350-2506@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Docetaxel (HB1801): Phase 2 readout est. (NCT06525350)
DESCRIPTION:Docetaxel (HB1801)\, phase 2\, Non-Small Cell Lung Cancer.\nStu
 dy: A Study to Evaluate the Efficacy and Safety of the Combination of Glum
 etinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment o
 f MET-overexpressed Non-small Cell Lung Cancer\nEstimated primary completi
 on: 25 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /docetaxel-hb1801#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06525350
URL:https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106372-1335@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:stapokibart: Phase 3 readout est. (NCT07106372)
DESCRIPTION:stapokibart\, phase 3\, Atopic Dermatitis.\nStudy: A Study of S
 tapokibatrt in Children Subjects With Atopic Dermatitis\nEstimated primary
  completion: February 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/stapokibart#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07106372
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136988-2291@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Enlonstobart: Phase 1/2 readout est. (NCT06136988)
DESCRIPTION:Enlonstobart\, phase 1/2.\nStudy: A Study of Docetaxel for Inje
 ction (Albumin-bound) and SG001 in Combination With Cisplatin and Simultan
 eous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Ca
 rcinoma.\nEstimated primary completion: April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/enlonstobart#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06136988
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684287-9069@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Sirolimus for Injection (Albumin-bound): Phase 2 readout est. (NCT0
 7684287)
DESCRIPTION:Sirolimus for Injection (Albumin-bound)\, phase 2.\nStudy: A Ph
 ase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Pr
 ogressive or Symptomatic Epithelioid Hemangioendothelioma\nEstimated prima
 ry completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sirolimus-for-injection-albumin-bound#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07684287
URL:https://assetmemo.bio/drug/sirolimus-for-injection-albumin-bound#upcomi
 ng-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805135-2506@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Docetaxel (HB1801): Phase 3 readout est. (NCT07805135)
DESCRIPTION:Docetaxel (HB1801)\, phase 3.\nStudy: A Study of HB1801 Versus 
 Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer\nEstimated 
 primary completion: 1 June 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/docetaxel-hb1801#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07805135
URL:https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282509-2291@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Enlonstobart: Phase 1/2 readout est. (NCT07282509)
DESCRIPTION:Enlonstobart\, phase 1/2.\nStudy: Safety and Efficacy of Paclit
 axel Liposome Arterial Infusion Combined With Systemic Therapy for Second-
 Line Treatment of Advanced Liver Cancer\nEstimated primary completion: 26 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlonstoba
 rt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7282509
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547333-1335@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20320429
DTEND;VALUE=DATE:20320430
SUMMARY:stapokibart: Phase 2/3 readout est. (NCT06547333)
DESCRIPTION:stapokibart\, phase 2/3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study of CM310 in Subjects With Moderate to Severe Chronic Obs
 tructive Pulmonary Disease\nEstimated primary completion: 29 April 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/stapokibart#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06547333
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05761028-1335@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:stapokibart: Phase 2/3 readout est. (NCT05761028)
DESCRIPTION:stapokibart\, phase 2/3\, Asthma.\nStudy: A Study of CM310 in S
 ubjects With Moderate to Severe Asthma\nEstimated primary completion: May 
 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/stapokibart#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0576102
 8
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
